Anti-TROP-2 antibody binds to TROP-2-expressing tumor cells and allows the selective delivery of cytotoxic agents, thereby enhancing therapeutic efficacy while minimizing off-target effects [13]. Here, TACSTD2 is linked to neoplasm.